Bionorica SE, Dept. Clinical & Scientific Affairs R&D, Neumarkt i. d. O.Pf., Germany.
Bionorica Research GmbH, Dept. Bioanalytics, Innsbruck, Austria.
Planta Med. 2023 Feb;89(2):140-147. doi: 10.1055/a-1821-8690. Epub 2022 May 6.
Sinupret extract (BNO 1016) and Gelomyrtol forte (ELOM-080) represent the two top-selling cold remedies in Germany nowadays. Whereas BNO 1016 is a typical immediate release coated tablet, ELOM-080 is an enteric-coated soft gelatin capsule. The latter formulation, however, is at risk of pharmacokinetic interactions affecting absorption, especially in cases of concomitant food intake. In the present pilot study, we investigated the risk of a possible food effect in three male beagle dogs. Single doses of BNO 1016 and ELOM-80 were administered under fasting and fed conditions. Blood was sampled up to 30 h post-administration and plasma concentrations of the characteristic ingredients of BNO 1016 as well as ELOM-080 analytes were determined. Pharmacokinetic parameters focusing on the rate and extent of absorption were derived. BNO 1016 analytes demonstrated a similar course in both the fasted and fed states. ELOM-080 analytes also showed a similar picture in the fasted state. However, lag times (time from administration to first quantifiable time point in plasma) of up to 2 h post-administration with corresponding time to reach maximum concentration (obtained directly from the measured concentration) values of 3 to 4 h were observed, reflecting a longer gastric residence time. In the fed state, ELOM-080 showed significant pharmacokinetic characteristics, suggesting a clear food effect. A major observation was a double peak phenomenon that could be observed in two of three dogs. Furthermore, lag times of some analytes, up to 3 - 4 h, and corresponding time to reach maximum concentration values, up to 6 - 8 h, occurred. In contrast to BNO 1016, these findings suggest that, as with other enteric-coated formulations, there may also be a significant risk for food effects with ELOM-080 in humans.
辛普雷特提取物(BNO 1016)和 Gelomyrtol forte(ELOM-080)是当今德国两种最畅销的感冒药。虽然 BNO 1016 是一种典型的普通速释包衣片,但 ELOM-080 是一种肠溶软胶囊。然而,这种制剂存在影响吸收的药代动力学相互作用的风险,尤其是在同时进食的情况下。在本初步研究中,我们在三只雄性比格犬中研究了潜在食物效应的风险。在禁食和进食条件下单次给予 BNO 1016 和 ELOM-80 单剂量。给药后 30 小时内采集血液,并测定 BNO 1016 特征成分和 ELOM-080 分析物的血浆浓度。得出重点关注吸收速率和程度的药代动力学参数。禁食和进食状态下,BNO 1016 分析物的过程相似。在禁食状态下,ELOM-080 分析物也呈现相似的结果。然而,给药后 2 小时内的滞后时间(从给药到血浆中第一个可定量时间点的时间)和达到最大浓度的时间(直接从测量浓度获得)值为 3 至 4 小时,反映出更长的胃滞留时间。在进食状态下,ELOM-080 表现出明显的药代动力学特征,表明存在明显的食物效应。一个主要的观察结果是在三只狗中的两只狗中可以观察到双峰现象。此外,一些分析物的滞后时间长达 3 至 4 小时,达到最大浓度的时间长达 6 至 8 小时。与 BNO 1016 不同,这些发现表明,与其他肠溶制剂一样,ELOM-080 也可能对人类产生显著的食物效应风险。